Navigation Links
Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
Date:9/23/2011

cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver including metastatic melanoma to the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relat
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
2. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
3. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
4. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
5. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
6. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
7. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
8. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
9. Delcath on Preliminary List of Additions to Russell Microcap® Index
10. Delcath to Present at the JMP Securities Research Conference
11. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group ... in Brazil , Russia ... China (BRIC) will see robust expansion ... increasingly favored over surgical procedures. Although revenues will be ... reimbursement challenges, prolonged device approval times and demand for ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... Ky. , Sept. 30, 2014 A ... tomography (OCT), offered a new look at the composition ... alter how physicians understand and treat the disease, a ... conducted at Baptist Health Lexington between September 2010 and ... of the Journal of the American College of ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: ... IIb study, EMBLEM™, showed that certain doses of epratuzumab ... in disease activity in adult patients with moderate to ... designed to evaluate the efficacy and safety of epratuzumab ...
... innovator of Packaging Execution Systems (PES) for the pharmaceutical ... engineering, automation and manufacturing optimization services company, today announced ... Service Provider (SSP). VCG will now sell, install and ... United States. The SSP program is ...
Cached Medicine Technology:Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 2Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 3Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 4Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 5Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 7Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 2Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 3
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Fat Burning ... specialist and best-selling author Mike Geary that is helping people ... their body into a fat-burning machine in less than 24 ... investigative review. , “In our culture that is becoming ... hard to decipher what is really fact and fiction when ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3
... Hammer toes, curly toes, crossover toes and bunions are not only ... a new report warns. According to a review published in ... of Orthopaedic Surgeons , deformities of the lesser toes, which includes ... as early as possible by an orthopaedic surgeon to avoid other ...
... of men undergoing surgery for prostate cancer expect better recovery ... attain one year after the operation, a University of Michigan ... to surgery, a small proportion of men had expected to ... the surgery than they had before it the exact ...
... a recent issue of Cancer Research, Daniel J. Powell, ... Laboratory Medicine and Obstetrics and Gynecology at the Perelman ... for the first time that engineered human T cells ... Ovarian cancer is the most lethal reproductive cancer ...
... In an innovative collaboration designed to speed the process ... California, San Diego Health Sciences announced today that UC ... life science research institutions across the country as part ... collaborative partnerships formed through the Centers for Therapeutic Innovation ...
... -- Smokers who light up right after they wake up in ... neck cancers than those who wait longer before having their first ... was released online Aug. 8 in advance of publication in an ... smokers have higher levels of nicotine and possibly other tobacco toxins ...
... Alexandria, VA Dale Browne, MD, of Winston Salem, ... and Neck Surgery (AAO-HNS) Distinguished Service Award at the ... OTO EXPO, in San Francisco, CA, September 11-14, 2011. ... professionals in recognition of extensive meritorious service through the ...
Cached Medicine News:Health News:Toe Deformities Should Be Treated Early: Experts 2Health News:Men have overly optimistic expectations about recovery from prostate cancer surgery, U-M study finds 2Health News:Penn study finds more effective approach against 'Achilles' heel' of ovarian cancer 2Health News:UCSD Health Sciences partners with Pfizer to speed drug delivery 2Health News:UCSD Health Sciences partners with Pfizer to speed drug delivery 3Health News: Early Morning Smoking Riskier For Cancer 2
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: